Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Larson

Showing results (261-270 of 300) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
The progress and promise of molecular imaging probes in oncologic drug developmentGary J Kelloff, Kenneth A Krohn, Steven M Larson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion UptakeNeeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman PrimatesDarren R Veach, Claire M Storey, Katharina Lückerath, et al.
Radiology|June 30, 2009
Feasibility of ex vivo FDG PET of the colonMarc J Gollub, Timothy J Akhurst, Matthew J Williamson, et al.
Annals of Surgery|November 29, 2012
Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective studyJosé G Guillem, Jeannine A Ruby, Tobias Leibold, et al.
Pageof 30

Showing results (261-270 of 300) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
The progress and promise of molecular imaging probes in oncologic drug developmentGary J Kelloff, Kenneth A Krohn, Steven M Larson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion UptakeNeeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman PrimatesDarren R Veach, Claire M Storey, Katharina Lückerath, et al.
Radiology|June 30, 2009
Feasibility of ex vivo FDG PET of the colonMarc J Gollub, Timothy J Akhurst, Matthew J Williamson, et al.
Annals of Surgery|November 29, 2012
Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective studyJosé G Guillem, Jeannine A Ruby, Tobias Leibold, et al.
Pageof 30